Agnieszka Grochowalska, MD
Endocrinology, Diabetes & Metabolism · Trumbull, CTNPI 1144496209
Payments from drug & device makers
Across 514 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$692
- Sanofi-aventis U.S. LLC$628
- Boehringer Ingelheim$557
- Amgen$520
- AstraZeneca$425
- plus $3K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 219 | $1,557 |
| Lilly USA, LLC | 40 | $692 |
| Sanofi-aventis U.S. LLC | 32 | $628 |
| Boehringer Ingelheim | 21 | $557 |
| Amgen | 20 | $520 |
| AstraZeneca(2 entities) | 18 | $425 |
| AbbVie | 27 | $424 |
| Abbott | 11 | $315 |
| Dexcom, Inc. | 11 | $267 |
| Amneal Pharmaceuticals LLC | 12 | $265 |
| IBSA Pharma Inc. | 12 | $258 |
| Insulet Corporation | 13 | $241 |
| Corcept Therapeutics | 8 | $196 |
| Medtronic(2 entities) | 9 | $192 |
| Johnson & Johnson | 12 | $188 |
| Radius Health, Inc. | 7 | $155 |
| Amarin Pharma, Inc. | 8 | $147 |
| Merck | 8 | $118 |
| Lifescan, Inc. | 5 | $107 |
| Ascendis Pharma Endocrinology Inc | 1 | $94 |
| Mannkind Corporation | 4 | $80 |
| Shire North American Group Inc | 2 | $37 |
| Tandem Diabetes Care, Inc. | 2 | $36 |
| Currax Pharmaceuticals LLC | 2 | $36 |
| BD | 2 | $34 |
| Cequr Corporation | 1 | $33 |
| Bayer | 1 | $30 |
| Pfizer | 2 | $25 |
| Senseonics, Incorporated | 1 | $24 |
| Valeritas, Inc. | 1 | $23 |
| Acerus Pharmaceuticals Corporation | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$7,735 in reported general payments places this provider in the 75th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Trumbull
- Glenn RichTrumbull$210K
- Judith CastilloTrumbull$37K
- Jonathan FillmoreTrumbull$12K
- Joseph RosaTrumbull$8K
- Erika StrohmayerTrumbull$4K
- Ania JastreboffNew Haven$2.2M
- Ilja HulinskyBridgeport$1.6M
- Gerald ShulmanNew Haven$1M
- Karl InsognaNew Haven$903K
- Clemens BergwitzNew Haven$735K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.